A study conducted in Hong Kong on more than a thousand patients shows that the Coronavac vaccine, developed by the Chinese laboratory Sinovac, causes the production of ten times less antibodies than the vaccine developed by BioNTech and produced by Pfizer.
This comparison between the two vaccines available in Hong Kong was conducted by researchers at the University of Hong Kong on 1,442 health workers who received two doses of these vaccines.
Published in the medical journal The Lancet Microbe on July 15, the article specifies that the quantity of antibodies is not sufficient to assess the level of immunity conferred by a vaccine, but that “the differences in the concentrations of neutralizing antibodies identified in our study could result in substantial differences in vaccine efficacy ”. The researchers add that patients who received Coronavac show similar antibody levels to patients who contracted Covid-19 and are cured.
